Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination.

human non-human primate vaccine yellow fever

Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
03 Apr 2024
Historique:
medline: 3 4 2024
pubmed: 3 4 2024
entrez: 3 4 2024
Statut: aheadofprint

Résumé

The non-human primate (NHP) model (specifically rhesus and cynomolgus macaques) has facilitated our understanding of the pathogenic mechanisms of yellow fever (YF) disease and allowed the evaluation of the safety and efficacy of YF-17D vaccines. However, the accuracy of this model in mimicking vaccine-induced immunity in humans remains to be fully determined. We used a systems biology approach to compare hematological, biochemical, transcriptomic, and innate and antibody-mediated immune responses in cynomolgus macaques and human participants following YF-17D vaccination. Immune response progression in cynomolgus macaques followed a similar course as in adult humans but with a slightly earlier onset. Yellow fever virus neutralizing antibody responses occurred earlier in cynomolgus macaques [by Day 7[(D7)], but titers > 10 were reached in both species by D14 post-vaccination and were not significantly different by D28 [plaque reduction neutralization assay (PRNT)

Identifiants

pubmed: 38567951
doi: 10.1128/jvi.01516-23
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0151623

Auteurs

Nathalie Mantel (N)

Research and Development, Sanofi, Marcy L'Etoile, France.

Fabienne Piras-Douce (F)

Research and Development, Sanofi, Marcy L'Etoile, France.

Emilie Chautard (E)

Research and Development, Sanofi, Marcy L'Etoile, France.

Ernesto Marcos-Lopez (E)

Université Paris-Saclay, INSERM, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay aux Roses, France.

Caroline L Bodinham (CL)

Surrey Clinical Research Centre, University of Surrey, Guildford, Surrey, United Kingdom.

Antonio Cosma (A)

Université Paris-Saclay, INSERM, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay aux Roses, France.

Virginie Courtois (V)

Research and Development, Sanofi, Marcy L'Etoile, France.

Nina Dhooge (N)

Université Paris-Saclay, INSERM, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay aux Roses, France.

Sylviane Gautheron (S)

Research and Development, Sanofi, Marcy L'Etoile, France.

Stefan H E Kaufmann (SHE)

Max Planck Institute for Infection Biology, Berlin, Germany; Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.
Hagler Institute for Advanced Study, Texas A&M University, College Station, Texas, USA.

Kathleen Pizzoferro (K)

Surrey Clinical Research Centre, University of Surrey, Guildford, Surrey, United Kingdom.

David J M Lewis (DJM)

Surrey Clinical Research Centre, University of Surrey, Guildford, Surrey, United Kingdom.

Frédéric Martinon (F)

Université Paris-Saclay, INSERM, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay aux Roses, France.

Anke Pagnon (A)

Research and Development, Sanofi, Marcy L'Etoile, France.

Franck Raynal (F)

Research and Development, Sanofi, Marcy L'Etoile, France.

Nathalie Dereuddre-Bosquet (N)

Université Paris-Saclay, INSERM, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay aux Roses, France.

Roger Le Grand (R)

Université Paris-Saclay, INSERM, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay aux Roses, France.

Classifications MeSH